Skip to content
Homepage
Author:
Zymeworks Inc.
Posted Date:
October 24, 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Inc.
October 24, 2026
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks Inc.
October 23, 2026
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
Zymeworks Inc.
October 19, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Zymeworks Inc.
October 15, 2026
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks Inc.
September 28, 2026
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc.
September 23, 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Zymeworks Inc.
August 25, 2026
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Zymeworks Inc.
July 16, 2026
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks Inc.
June 29, 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks Inc.
June 15, 2026
